Delivery Order SPE2DB22D1106-SPE2DB25FFFC1
- Not listed
- The Defense Logistics Agency awarded a $44,398.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This competitive, firm fixed-price contract was executed on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $2,603.55 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance completed by August 13, 2025. This non-set-aside contract reflects a firm fixed-price delivery order issued under competitive procedures. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $3,783.70 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, competitively awarded contract was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Repatha is a prescription medication used to lower cholesterol...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, valued at $10,789.86 under a firm fixed price contract. The award was issued on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a non-set-aside, competitively awarded procurement. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $15,891.48 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 1, 2025. This firm fixed-price, competitively awarded delivery order was issued under no set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.56 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency has awarded a delivery order valued at $37,819.00 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector medication. This competitively awarded, firm fixed-price contract was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,540.44 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania and completion by August 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a routine pharmaceutical supply transaction within the federal medical procurement system. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $41,766.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, which is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), carries an ultimate completion date of August 22, 2025. This award was competitively granted with no...
- The Defense Logistics Agency awarded a delivery order valued at $40,273.98 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. Repatha is a PCSK9 inhibitor used to treat high...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFFC1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at approximately $78K to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 26, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Repatha is a PCSK9 inhibitor used for cardiovascular disease management, reflecting the company's role in delivering specialty medications across multiple therapeutic domains for Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $78.0k | 8/25/25 |